Apologies for my lack of contribution here. I've tried my best...

Apologies for my lack of contribution here. I've tried my best to bottom draw this with full confidence on the teams ability to deliver a part 2 CSL over the next 10 years.

May key question here is:

- 2024 full year guidance of 705 million for worldwide sales of illuccix. "Guidance will be updated as appropriate to reflect product approvals"
- So is this illuccix sales projectory for US, Canada and Australia only?

- Does this not include EU sales as its not yet approved there?

Assuming it doesn't include:
- EU sales
- Asia sales
- Zircaix sale
- Pixclara sales

Then I wouldn't be surprised to see 1 billion $ rev + in the next 11 months if most are commercially available (even considering the slower ramp up from approval to roll out).

I bang my head on the table wondering why it's so cheap. I'm pre-empting an explosive move when it clears into the $13-$14 blue sky range

Other interpretations would be appreciated